Menarini poised for upside from Radius deal as breast cancer results point to submission

A new Phase III readout for elacestrant in breast cancer sets up Menarini to reap rewards from a 2020 deal in which the Italian biopharma showed a willingness to assume a level of risk that partner Radius would not.

The partners are planning regulatory submissions next year in the U.S. and EU after elacestrant, a selective estrogen receptor degrader (SERD), met both primary endpoints in the Phase III EMERALD trial to treat hormone receptor-positive, HER2-negative breast cancer. Elacestrant led to progression-free survival benefits among the study’s overall population and in a subgroup with ESR1 mutations...